Mineralys Therapeutics Inc — Cash Flow (NASDAQ:MLYS)

Financials

Cash from operating activities -81.17 M-166.31 M-142.42 M -142.42 M Cash from investing activities -160.47 M114.96 M-389.75 M -389.75 M Cash from financing activities 203.25 M116.14 M591 M 591 M Free cash flow -81.17 M-166.41 M-142.43 M -142.43 M

뉴스

제퍼리스, Mineralys Therapeutics 목표 주가 하향 조정

Jefferies cuts Mineralys Therapeutics price target on drug concerns

Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS)

스티펠, Mineralys 주식에 ’매수’ 등급 재확인, 목표가 52달러

Stifel reiterates Buy rating on Mineralys stock, $52 target

BofA, Mineralys Therapeutics 목표 주가 상향

BofA raises Mineralys Therapeutics stock price target on NDA progress

Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript

미네랄리스, FDA 로룬드로스타트 결정 임박…실적 집중

Mineralys earnings in focus as FDA lorundrostat decision looms

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug

스티펠, 로룬드로스타트 데이터에 미네랄리스 테라퓨틱스 투자의견 재확인